Literature DB >> 23357313

Comparative analysis of interactions of RASSF1-10.

Jia Jia Chan1, Delphine Flatters, Fernando Rodrigues-Lima, Jun Yan, Konstantinos Thalassinos, Matilda Katan.   

Abstract

Members of the RASSF family (RASSF1-10) have been identified as candidate tumour suppressors that are frequently downregulated by promoter hypermethylation in cancers. These proteins carry a common Ras-association (RA) and SARAH domain (RASSF1-6) that can potentially bind Ras oncoproteins and mediate protein-protein interactions with other SARAH domain proteins. However, there is a notable lack of comparative characterisation of the RASSF family, as well as molecular and structural information that facilitate their tumour suppressive functions. As part of our comparative analysis, we modelled the RA and SARAH domains of the RASSF members based on existing structures and predicted their potential interactions. These in silico predictions were compared to in vitro interaction studies with Ras and MST kinase (a SARAH domain-containing protein). Our data shows a diversity of interaction within the RASSF family RA domain, whereas the SARAH domain-mediated interactions for RASSF1-6 are consistent with the predictions. This suggests that different members, despite shared general architecture, could have distinct functional properties. Additionally, we identify a new interacting partner for MST kinase in the form of RASSF7. Current data supports an interaction model where RASSF serves as an adaptor for the assembly of multiple protein complexes and further functional interactions, involving MST kinases and other SARAH domain proteins, which could be regulated by Ras.
Copyright © 2012 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23357313      PMCID: PMC4221134          DOI: 10.1016/j.jbior.2012.12.001

Source DB:  PubMed          Journal:  Adv Biol Regul        ISSN: 2212-4926


  38 in total

1.  RASSF7 negatively regulates pro-apoptotic JNK signaling by inhibiting the activity of phosphorylated-MKK7.

Authors:  S Takahashi; A Ebihara; H Kajiho; K Kontani; H Nishina; T Katada
Journal:  Cell Death Differ       Date:  2010-11-19       Impact factor: 15.828

Review 2.  A novel interaction motif, SARAH, connects three classes of tumor suppressor.

Authors:  Hartmut Scheel; Kay Hofmann
Journal:  Curr Biol       Date:  2003-12-02       Impact factor: 10.834

3.  Dimerization-induced folding of MST1 SARAH and the influence of the intrinsically unstructured inhibitory domain: low thermodynamic stability of monomer.

Authors:  Diana Constantinescu Aruxandei; Cihan Makbul; Agne Koturenkiene; Maik-Borris Lüdemann; Christian Herrmann
Journal:  Biochemistry       Date:  2011-12-02       Impact factor: 3.162

4.  Nore1 and RASSF1 regulation of cell proliferation and of the MST1/2 kinases.

Authors:  Joseph Avruch; Maria Praskova; Sara Ortiz-Vega; Matthew Liu; Xian-Feng Zhang
Journal:  Methods Enzymol       Date:  2006       Impact factor: 1.600

Review 5.  Coiled coils: new structures and new functions.

Authors:  A Lupas
Journal:  Trends Biochem Sci       Date:  1996-10       Impact factor: 13.807

6.  Characterization of interactions of adapter protein RAPL/Nore1B with RAP GTPases and their role in T cell migration.

Authors:  Mandy Miertzschke; Paula Stanley; Tom D Bunney; Fernando Rodrigues-Lima; Nancy Hogg; Matilda Katan
Journal:  J Biol Chem       Date:  2007-08-23       Impact factor: 5.157

7.  RASSF4/AD037 is a potential ras effector/tumor suppressor of the RASSF family.

Authors:  Kristin Eckfeld; Luke Hesson; Michele D Vos; Ivan Bieche; Farida Latif; Geoffrey J Clark
Journal:  Cancer Res       Date:  2004-12-01       Impact factor: 12.701

8.  Ras-association domain family protein 6 induces apoptosis via both caspase-dependent and caspase-independent pathways.

Authors:  Mitsunobu Ikeda; Susumu Hirabayashi; Naoyuki Fujiwara; Hiroki Mori; Akira Kawata; Junko Iida; Yijun Bao; Yuji Sato; Tadatsune Iida; Haruhiko Sugimura; Yutaka Hata
Journal:  Exp Cell Res       Date:  2007-02-23       Impact factor: 3.905

9.  RAN GTPase is a RASSF1A effector involved in controlling microtubule organization.

Authors:  Ashraf Dallol; Luke B Hesson; David Matallanas; Wendy N Cooper; Eric O'Neill; Eamonn R Maher; Walter Kolch; Farida Latif
Journal:  Curr Biol       Date:  2009-06-25       Impact factor: 10.834

10.  RASSF2 associates with and stabilizes the proapoptotic kinase MST2.

Authors:  W N Cooper; L B Hesson; D Matallanas; A Dallol; A von Kriegsheim; R Ward; W Kolch; F Latif
Journal:  Oncogene       Date:  2009-06-15       Impact factor: 9.867

View more
  17 in total

Review 1.  Phosphoinositide-specific phospholipase C in health and disease.

Authors:  Lucio Cocco; Matilde Y Follo; Lucia Manzoli; Pann-Ghill Suh
Journal:  J Lipid Res       Date:  2015-03-27       Impact factor: 5.922

2.  Alveolar rhabdomyosarcoma-associated PAX3-FOXO1 promotes tumorigenesis via Hippo pathway suppression.

Authors:  Lisa E S Crose; Kathleen A Galindo; Julie Grondin Kephart; Candy Chen; Julien Fitamant; Nabeel Bardeesy; Rex C Bentley; Rene L Galindo; Jen-Tsan Ashley Chi; Corinne M Linardic
Journal:  J Clin Invest       Date:  2013-12-16       Impact factor: 14.808

3.  E4BP4/NFIL3 modulates the epigenetically repressed RAS effector RASSF8 function through histone methyltransferases.

Authors:  Isai Pratha Karthik; Pavitra Desai; Sudarkodi Sukumar; Aleksandra Dimitrijevic; Krishnaraj Rajalingam; Sundarasamy Mahalingam
Journal:  J Biol Chem       Date:  2018-02-21       Impact factor: 5.157

4.  The RASSF6 tumor suppressor protein regulates apoptosis and the cell cycle via MDM2 protein and p53 protein.

Authors:  Hiroaki Iwasa; Takumi Kudo; Sainawaer Maimaiti; Mitsunobu Ikeda; Junichi Maruyama; Kentaro Nakagawa; Yutaka Hata
Journal:  J Biol Chem       Date:  2013-09-03       Impact factor: 5.157

Review 5.  Tumor suppressor C-RASSF proteins.

Authors:  Hiroaki Iwasa; Shakhawoat Hossain; Yutaka Hata
Journal:  Cell Mol Life Sci       Date:  2018-01-20       Impact factor: 9.261

6.  MST2-RASSF protein-protein interactions through SARAH domains.

Authors:  Goar Sánchez-Sanz; David Matallanas; Lan K Nguyen; Boris N Kholodenko; Edina Rosta; Walter Kolch; Nicolae-Viorel Buchete
Journal:  Brief Bioinform       Date:  2015-10-05       Impact factor: 11.622

7.  RASSF4 is required for skeletal muscle differentiation.

Authors:  Yi-Tzu Lin; Michael D Deel; Corinne M Linardic
Journal:  Cell Biol Int       Date:  2019-09-25       Impact factor: 3.612

8.  A comprehensive analysis of RAS-effector interactions reveals interaction hotspots and new binding partners.

Authors:  Soheila Rezaei Adariani; Neda S Kazemein Jasemi; Farhad Bazgir; Christoph Wittich; Ehsan Amin; Claus A M Seidel; Radovan Dvorsky; Mohammad R Ahmadian
Journal:  J Biol Chem       Date:  2021-04-27       Impact factor: 5.157

Review 9.  RASSF6; the Putative Tumor Suppressor of the RASSF Family.

Authors:  Hiroaki Iwasa; Xinliang Jiang; Yutaka Hata
Journal:  Cancers (Basel)       Date:  2015-12-09       Impact factor: 6.639

10.  Screening for protein-protein interactions using Förster resonance energy transfer (FRET) and fluorescence lifetime imaging microscopy (FLIM).

Authors:  Anca Margineanu; Jia Jia Chan; Douglas J Kelly; Sean C Warren; Delphine Flatters; Sunil Kumar; Matilda Katan; Christopher W Dunsby; Paul M W French
Journal:  Sci Rep       Date:  2016-06-24       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.